Mode
Text Size
Log in / Sign up
N/A N=89 Randomized Single-blind Prevention

The Effect of Anesthesia on Neurodevelopmental Outcome (NDO)

Anesthesia; Adverse Effect · Congenital Heart Disease · Neurodevelopmental Disorders

Enrolled (actual)
89
Serious AEs
19.1%
Results posted
May 2022
Primary outcome: Primary: Bayley III — 91; 93; 88; 90 score on a scale

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Isoflurane (Drug); Fentanyl (high dose) (Drug); Fentanyl (low dose) (Drug)
Age
Pediatric · 0+ yrs
Sex
All
Sponsor
Stanford University
Primary completion
Nov 2020

Outcome Measures

OutcomeResultp-value
PRIMARY
Bayley III
91; 93; 88; 90; 97; 90
PRIMARY
Electroencephalogram
0; 0; 1; 1; 0; 1
SECONDARY
Choline
SECONDARY
Glutamate
SECONDARY
N-acetylaspartate (Naa)
SECONDARY
Lactate

Summary

The purpose of this study is to assess whether the type of anesthesia, narcotic-based versus inhalational anesthesia administered during cardiopulmonary bypass (CPB) surgery contributes to the wide variation in neurologic recovery and developmental outcome after surgery in infants with congenital heart disease.

Eligibility Criteria

Inclusion Criteria

  • Neonates of at least 32 weeks of gestation, infants and children up to 2 years of age admitted to The Children's Hospital for treatment of cyanotic or non-cyanotic heart disease requiring surgical intervention.
  • Admitting diagnosis of cyanotic or non-cyanotic heart disease

Exclusion Criteria

  • Neonates less than 32 weeks of gestational age, and children more than 2 years of age.
  • Any documented central nervous system malformations.
  • Any potential subject requiring unexpected postoperative Extracorporeal membrane oxygenation (ECMO) support
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03882788). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search